BioCentury
ARTICLE | Clinical News

Bavarian Nordic reports ProstVac data

May 18, 2012 11:29 PM UTC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac in combination with Quadramet led to a progression-free survival rate at four months of 29.4% vs. 11.8% for Quadramet alone in a Phase II trial to treat castration-resistant prostate cancer (CRPC) with bone metastases. Median PFS was 117 days for ProstVac plus Quadramet vs. 60 days for Quadramet alone. Data will be presented at the American Society of Clinical Oncology meeting that starts June 1 in Chicago. The data were from 34 evaluable patients who were previously treated with docetaxel. ProstVac is a vaccine targeting PSA that also contains a Tricom triad of costimulatory molecules -- CD58 (LFA-3), intercellular adhesion molecule-1 ( ICAM-1; CD54) and CD80 (B7-1). ...